Akero (NASDAQ:AKRO) shares soared Monday on encouraging data from a Phase 2b study of efruxifermin in the treatment of patients with compensated cirrhosis (F4) due to MASH, also known as metabolic ...

Explore the promising potential of Altimmune, Inc.'s Pemvidutide in NASH, AUD, & obesity treatment, with key trials underway.

HistoIndex, a global leader in stain-free digital pathology solutions for managing fibrotic diseases, has announced the ...